YC 1

Drug Profile

YC 1

Latest Information Update: 09 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yung Shin Pharmaceutical
  • Developer Bayer; Yung Shin Pharmaceutical
  • Class Antiplatelets; Ischaemic heart disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Myocardial infarction; Thrombosis

Most Recent Events

  • 11 Jun 1997 Preclinical development for Angina pectoris in Germany (Unknown route)
  • 11 Jun 1997 Preclinical development for Myocardial infarction in Germany (Unknown route)
  • 11 Jun 1997 A study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top